Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BERGEN's $40 MIL. DIVESTITURE OF MEDICAL/SURGICAL UNIT to a private investor group will focus the wholesaler more closely on its core drug distribution business. "The benefits of this restructuring should provide an opportunity to further improve performance in the company's other lines of business," Chairman Emil Martini, Jr., declared in a Nov. 9 press release. For the most recent fiscal year (ended Aug. 31), Bergen Brunswig Medical Supply generated revenues of $247 mil., down from $271 mil. in fiscal 1986, and accounted for about 7% of the parent company's total $3.4 bil. volume. While Bergen's medical/surgical business grew about 10% in fiscal 1986, the division's operating earnings dropped from $6 mil. to $5 mil. Led by New York investor Polyvios Vintiadis, the purchasing group will include "key management" from Bergen Brunswig Medical Supply, including current President Paul Jordan. Vintiadis, a principal in the firm Morgens, Waterfall, Vintiadis & Co., indicated in a separate Nov. 9 release that the acquisition would be the first of several future health care investments. "This is the platform for building a national medical supply company," he said, noting that acquisitions are planned in other regions to complement the West Coast presence. Bergen's medical/surgical business grew as a by-product of the ongoing consolidation in the wholesale drug industry. In a series of acquisitions that ended about 18 months ago, the company increased its total revenues by 50%. Between the 1984 and 1985 fiscal years, medical/surgical sales rose nearly 50% to $246 mil., primarily as a result of the acquisition of Synergex in January 1985. That $79 mil. purchase added over $60 mil. in medical/surgical sales as well as $270 mil. in drug volume. Debt financing for the deal, expected to close in January 1988, is being supplied by Bankers Trust Company. Bergen Brunswig, which expects to record a gain on the sale, reported $15.9 mil. in net earnings for fiscal 1987, an increase of 14%. In addition to the drug wholesale operation, Bergen also distributes a line of consumer electronic products and video software through its Commtron subsidiary. Commtron revenues reached $440 mil. in fiscal 1986, up 40% from the previous year.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts